497.06% 0.0845

Galera Therapeutics Inc (GRTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché GRTX Giù? Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Galera Therapeutics Inc Stock (GRTX) Company Profile

Galera Therapeutics Inc

Healthcare (1107)

Biotechnology (615)

Prossima data di guadagno

Ultimi documenti SEC

GRTX's Discussions on Twitter

Compare GRTX vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GRTX Galera Therapeutics Inc	0.1015	0	0	149.05M	-6.05M	1.9846
VRTX Vertex Pharmaceuticals Inc	425.43	109.41B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	706.85	76.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	784.44	48.20B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	302.35	40.31B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	295.54	33.13B	5.36B	287.73M	924.18M	2.5229

Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-08-10	Downgrade	Piper Sandler	Overweight → Neutral
2021-10-19	Downgrade	BTIG Research	Buy → Neutral
2021-10-19	Downgrade	BofA Securities	Buy → Underperform
2021-04-26	Ripresa	Credit Suisse	Outperform
2020-12-16	Aggiornamento	Credit Suisse	Neutral → Outperform
2020-12-07	Iniziato	H.C. Wainwright	Buy
2019-12-02	Iniziato	BTIG Research	Buy
2019-12-02	Iniziato	BofA/Merrill	Buy
2019-12-02	Iniziato	Citigroup	Buy
2019-12-02	Iniziato	Credit Suisse	Neutral

Mostra tutto

Galera Therapeutics Inc Borsa (GRTX) Ultime notizie

Galera Therapeutics Inc Azioni (GRTX) Dati Finanziari

Galera Therapeutics Inc (GRTX)

Galera Therapeutics Inc Stock (GRTX) Company Profile

Compare GRTX vs VRTX, REGN, ARGX, ALNY, ONC

Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades

Galera Therapeutics Inc Borsa (GRTX) Ultime notizie

Malvern-based Galera Therapeutics to be acquired in reverse merger - MSN

Emerald backs Galera–Obsidian deal with 26.5% Galera (GRTX) stake - Stock Titan

Galera, Obsidian Agree to Merge, Raise $350 Million in Financing - MyChesCo

Obsidian CEO Madan Jagasia Leads Merger with Galera Therapeutics Backed by $350M Financing - INDIA New England News

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger-LEG, AVNS, GRTX, and GSAT - The Malaysian Reserve

Halper Sadeh LLC is Investigating Whether LEG, AVNS, SEM, GRTX are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.

Merger Deal: Galera Therapeutics (GRTX) to Merge with Obsidian; ASCO Phase 2 Data Ahead - Stock Titan

Galera Therapeutics (NASDAQ: GRTX) to merge with Obsidian; S-4 and proxy planned - Stock Titan

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--LEG, AVNS, GRTX, and GSAT - Sahm

Galera, Obsidian to Merge, Raise $350 Million in Financing - MyChesCo

Are FORA, GRTX, WBS, TALK Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve

[DEF 14A] Galera Therapeutics, Inc. Definitive Proxy Statement - Stock Titan

United StatesGoodwin Advises Obsidian Therapeutics On Merger With Galera Therapeutics And $350 Million Private Placement Financing - Mondaq

Galera Therapeutics to merge with Obsidian in $350M deal By Investing.com - Investing.com Australia

Obsidian and Galera reveal reverse merger plan - The Pharma Letter

Obsidian, Galera to advance cell therapy following reverse merger - BioPharma Dive

Galera (GRTX) to Merge with Obsidian; $350M Financing Backs OBX‑115 - Stock Titan

M&A Class Action Firm Investigating Galera Acquisition - National Today

Galera and Obsidian Announce $350M Merger, Advancing Novel TIL Therapies - National Today

Merger: Galera to combine with Obsidian (NASDAQ: GRTX) with $350M PIPE commitment - Stock Titan

Obsidian Therapeutics (NASDAQ: OBX) to list after merger with Galera, $350M PIPE - Stock Titan

Galera Therapeutics (GRTX) to file Form S-4 for proposed Obsidian merger - Stock Titan

Galera Therapeutics (GRTX) to Merge with Obsidian Therapeutics - GuruFocus

Obsidian Therapeutics, Inc. agreed to acquire Galera Therapeutics, Inc. in a reverse merger transaction. - marketscreener.com

Galera Therapeutics to merge with Obsidian in $350M deal - Investing.com

Galera Therapeutics, Obsidian Therapeutics Announce Merger and $350M Private Placement - citybiz

GRTX | GALERA THERAPEUTICS INC Insider Trading - Quiver Quantitative

GRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - Bluefield Daily Telegraph

Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement - ChartMill

Cell therapy biotech Obsidian leverages Galera reverse merger to go public - Fierce Biotech

Galera Therapeutics, Obsidian Therapeutics enter merger agreement - TipRanks

Galera Announces Obsidian Merger and $350M Financing - TipRanks

Galera Therapeutics (GRTX) to combine with Obsidian after $350M PIPE financing - Stock Titan

Galera Therapeutics to Merge With Obsidian; Secures $350 Million PIPE and Sets CVR for Legacy Assets - TradingView

Obsidian–Galera (OTC: GRTX) merger adds $350M PIPE to fund OBX-115 - Stock Titan

Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement - Weekly Voice

GALERA THERAPEUTICS INCCO AND OBSIDIAN TO MERGE IN ALL-STOCK DEAL - Moomoo

[PRE 14A] Galera Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan

Nancy T. Chang Discloses Investment at Galera Therapeutics with 5.9% Stake - TradingView

Director grows Galera (NASDAQ: GRTX) stake via private placement and merger - Stock Titan

Galera Therapeutics, Inc. Files Form 8-K: Company Information, Stock Symbol GRTX, and No Exchange Listing as of April 2026 - Minichart

Galera Therapeutics Announces Share Conversions and Warrant Exercise - TipRanks

Galera Therapeutics (GRTX) director IRA converts 5.34M preferred-linked shares - Stock Titan

[Form 4] Galera Therapeutics, Inc. Insider Trading Activity - Stock Titan

Preferred conversion and warrant exercise reshape Galera (GRTX) common stock - Stock Titan

Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary - Business Wire

Galera Sets Deadlines for 2026 Combined Annual Meeting - The Globe and Mail

Galera Therapeutics schedules combined 2025 and 2026 annual meeting for May - Investing.com Australia

Galera Therapeutics schedules combined 2025-2026 annual meeting for May 8, 2026; April 13 proposal deadline - TradingView

Galera Therapeutics (GRTX) sets 2026 meeting date and April 13 proposal deadline - Stock Titan

Galera Therapeutics 10-K: Revenue $0, EPS $0.64 on $149.0M Net Income - TradingView

Galera Therapeutics Inc Azioni (GRTX) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a GRTX